✦ LIBER ✦

817 POSITIVE PREDICTIVE VALUE OF EARLY ANTIVIRAL RESPONSE PROFILE WITH ALBINTERFERON ALFA-2B IN IFN-NAIVE PATIENTS WITH GENOTYPE 1, CHRONIC HEPATITIS C

✍ Scribed by A.U. Neumann; S. Zeuzem; E. Yoshida; Y. Benhamou; S. Pianko; J.G. McHutchison; E. Pulkstenis; G.M. Subramanian

Book ID: 117376743
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 59 KB
Volume: 48
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(08)60819-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

819 HEALTH-RELATED QUALITY OF LIFE (HRQO

✍ S. Pianko; E. Yoshida; S. Zeuzem; Y. Benhamou; V. Bain; E. Pulkstenis; J.G. McHu 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Albinterferon alfa-2b dosed every two or

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C

✍ Stefan Zeuzem; Eric M. Yoshida; Yves Benhamou; Stephen Pianko; Vincent G. Bain; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 528 KB

The efficacy and safety of albinterferon alfa-2b (alb-IFN), a novel recombinant protein consisting of interferon alfa-2b genetically fused to human albumin, was evaluated in a phase 2b, open-label study of patients with genotype 1, chronic hepatitis C. In all, 458 IFN-alfa treatment-naı ¨ve patients

[779] ANTIVIRAL RESPONSE AT WEEK 12 FOLL

[779] ANTIVIRAL RESPONSE AT WEEK 12 FOLLOWING COMPLETION OF TREATMENT WITH ALBINTERFERON a-2b PLUS RIBAVIRIN IN GENOTYPE 1, IFN-NAIVE, CHRONIC HEPATITIS C PATIENTS

✍ S. Zeuzem; Y. Benhamou; V. Bain; D. Shouval; S. Pianko; R. Flisiak; M. Grigoresc 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 133 KB

818 VIRAL KINETICS AND PHARMACODYNAMICS

818 VIRAL KINETICS AND PHARMACODYNAMICS OF ALBINTERFERON ALFA-2B IN INTERFERON TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1, CHRONIC HEPATITIS C

✍ A.U. Neumann; L. Rozenberg; V.G. Bain; J.G. McHutchison; E. Pulkstenis; G.M. Sub 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Early prediction of sustained virologica

Early prediction of sustained virological response at day 3 of treatment with albinterferon-α-2b in patients with genotype 2/3 chronic hepatitis C

✍ Avidan U. Neumann; Vincent G. Bain; Eric M. Yoshida; Keyur Patel; Erik Pulksteni 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB

Prediction of response to peginterferon-

Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b

✍ Yoshimasa Hashimoto; Hidenori Ochi; Hiromi Abe; Yasufumi Hayashida; Masataka Tsu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 1 views

## Abstract Variation at the IL‐28B locus was recently reported to be a significant predictive factor of viral response to pegylated‐interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL‐28B polymorphism rs8099917 and v